louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03519386: Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Official title: Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glaucoma, Open-Angle
Ocular Hypertension
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2018-05-09
Enrollment: 590
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Detailed description: This is a prospective, randomized, double-masked, active-controlled, parallel-group, multi-center trial comparing the efficacy and safety of the Model G2TR 063 Travoprost Intraocular Implant and the Model G2TR-125 Travoprost Intraocular Implant to topical timolol in subjects with OAG or OHT. The staff who record key efficacy measures and the study subjects will remain masked to study treatment.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with open-angle glaucoma or ocular hypertension.
* C/D ratio ≤ 0.8
* Zero to three preoperative ocular hypotensive medications

Exclusion Criteria:

* Active corneal inflammation or edema.
* Retinal disorders not associated with glaucoma.

Primary outcomes:
measure: Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative
timeFrame: 3 months
Secondary outcomes:
measure: Mean IOP (Control Group vs. Each Implant Group) Through 12 Months Postoperative
timeFrame: 12 months
Other outcomes:
Locations:
city: Sioux Falls
country: United States
facility: Vance Thompson Vision
state: South Dakota
Study officials:
affiliation: Glaukos Corporation
name: Kerry Stephens, O.D.
role: STUDY_CHAIR
References:
citation: Belamkar A, Harris A, Zukerman R, Siesky B, Oddone F, Verticchio Vercellin A, Ciulla TA. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. Ann Med. 2022 Dec;54(1):343-358. doi: 10.1080/07853890.2021.1955146.
Clinical trial NCT00378586: Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock
Official title: Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Septic Shock
Lead sponsor: Herlev Hospital
Sponsor class: OTHER
First posted: 2006-09-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Septic shock patients.

Brief summary: Life-threatening infection impairs bloodflow to the gut, thereby causing less delivery of oxygen. This leads to increased formation of different inflammatory and infectious markers.

The investigators hypothesize, therefore, that there is a significant difference in the concentrations of inflammatory and infectious markers in the rectal mucosa between patients with septic shock and healthy controls.


Eligibility criteria: Inclusion Criteria:

* Septic shock

Exclusion Criteria:

* Age \< 18 years
* No next of kin
* Pathology of the descending or sigmoid colon or rectum
* Pregnancy
* 1st degree relatives with inflammatory bowel disease
* Severe coagulopathy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Dept. of Intensive Care 4131
Study officials:
affiliation: Dept. of Intensive Care 4131, Rigshospitalet, Copenhagen, Denmark
name: Michael Ibsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01366586: Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag
Official title: Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7 Antigen
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastric Cancer
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2011-06-06
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with endoscopically diagnosed gastric cancer

Brief summary: The study aims to:

1. Achieve molecular imaging of MG7 antigen in patients with gastric cancer in vivo using confocal laser endomicroscopy.
2. Compare the results of in vivo MG7-specific molecular imaging with CLE and ex vivo immunohistochemistry .

Detailed description: Gastric cancer remains the world's second leading cause of cancer-related death. Improved prognosis essentially depend on earlier diagnosis. Gastric monoclonal antibody MG7 has been validated as a specific antibody in gastric cancerous tissue. Conventional evaluation of MG7 antigen expression is immunohistochemistry, which is time-consuming, and the immunoreactivity can be affected by storage and fixation of tissue. Confocal laser endomicrosopy enables visualization of the cellular and subcellular structures in vivo. Thus this study aims to achieve molecular imaging of MG7 antigen in gastric cancer in vivo using confocal laser endomicroscopy.

Eligibility criteria: Inclusion Criteria:

* patients with endoscopically diagnosed gastric cancer

Exclusion Criteria:

* Patients who are allergic to fluorescein sodium
* Patients who are unwilling to sign or give the informed consent form
* Patients with giant tumors or obvious GI tract bleeding which make it hard or impossible to observe the lesions
* Patients with impaired cardiac, liver or renal function
* Patients with coagulopathy
* Patients with pregnancy or breastfeeding

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology, Qilu Hospital, Shandong University
state: Shandong
Study officials:
affiliation: Department of Gastroenterology, Qilu Hospital
name: Yanqing Li, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00434486: Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606
Official title: An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606 Administered Orally to Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-02-13
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To investigate a potential pharmacokinetic interaction between SKI-606 and ketoconazole when co-administered.


Eligibility criteria: Inclusion Criteria:

* Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG.

Primary outcomes:
measure: Pharmacokinetics; safety and tolerability
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
state: Pennsylvania
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT06065163: Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome
Official title: Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiorenal Syndrome Type 1
Lead sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
Sponsor class: OTHER
Collaborators: name: EchoNous Inc.
First posted: 2023-10-03
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Experimental, randomized, double-blind, and prospective study
Primary purpose: TREATMENT

Brief summary: A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.


Eligibility criteria: Inclusion Criteria:

* 18 years old or older
* Type 1 cardiorenal syndrome in emergency room at Instituto Nacional de Cardiologia Ignacio Chávez

Exclusion Criteria:

* Patients who denied to participate
* Liver disease (cirrohsis)
* Complex congenital heart disease
* Kidney transplant
* Heart transplant
* Severe valvular disease
* Chronic kidney disease KDIGO G5 and G5d
* INTERMACS Score 2

Primary outcomes:
measure: Decongestion within 7 days
timeFrame: 7 days
Secondary outcomes:
measure: Acutely decompensated heart failure readmission rate
timeFrame: 7 days
measure: Length of hospital stay
timeFrame: 7 days
measure: Total diuretic dose within 7 days
timeFrame: 7 days
measure: Number of participants that initiate kidney replacement therapy
timeFrame: 30 days
measure: Intrahospital mortality
timeFrame: 30 days
measure: Days alive out of hospital
timeFrame: 1 month
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Instituto Nacional de Cardiología Ignacio Chávez
Study officials:
References:
Clinical trial NCT03602963: Comparison Between Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System and the FreeStyle Libre Flash Glucose Monitoring System
Official title: A Comparative Study on the Accuracy and Usability Between the Dexcom G5 Mobile CGM System and the FreeStyle Flash Glucose Monitoring System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 1 Diabetes Mellitus
Keywords: Diabetes Mellitus
Child
Glucose sensor
Accuracy
Usability
Lead sponsor: Jessa Hospital
Sponsor class: OTHER
First posted: 2018-07-27
Enrollment: 10
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with type 1 diabetes mellitus treated with insulin injections

Brief summary: 1. The accuracy of the sensors (Dexcom G5 vs FreeStyle Libre Flash glucose monitoring) will be evaluated by simultaneous wearing of the 2 sensors during 2 weeks. During these 2 weeks the patients will do at least four capillary blood glucose measurements to compare with the sensor results.
2. Patient satisfaction will be evaluated using a questionnaire that will be completed after the Dexcom G5 sensor has been worn for 1 month.
3. The data recorded by the FreeStyle Libre Flash glucose monitoring system (average glucose,% above target, % within target, % under target, amount of hypoglycemia) in the month prior to the 2 weeks of double sensor wear will be compared to the same data recorded by the Dexcom G5 mobile CGM system during the first month of use.


Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes mellitus
* Treated by insulin injections

Exclusion Criteria:

* Other types of diabetes
* Treated with insulin pump

Primary outcomes:
measure: Accuracy of the Dexcom G5 mobile continuous glucose monitoring (CGM) system by comparison of sensor glucose measurements with capillary blood glucose determinations
timeFrame: 2 weeks
Secondary outcomes:
measure: Patients' and parents' satisfaction with the Dexcom G5 mobile CGM system will be evaluated by a standardized questionnaire
timeFrame: 1 month
Other outcomes:
Locations:
city: Hasselt
country: Belgium
facility: Jessa Hospital
state: Limburg
Study officials:
affiliation: Jessa Hospital
name: Guy Massa, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02239263: N6 Input Processing in Traditional CI Recipients
Official title: Investigation of Nucleus 6 Sound Processor Input Processing in Cochlear Implant Recipients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss
Lead sponsor: Cochlear
Sponsor class: INDUSTRY
First posted: 2014-09-12
Enrollment: 40
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the enhanced signal processing features of the Nucleus 6 Sound Processor on existing Nucleus cochlear implant recipients currently using the Nucleus 5 Sound Processor.


Eligibility criteria: Inclusion Criteria:

* Greater than 12 years
* Unilateral cochlear implant recipient (CI24RE, CI500, CI422)
* Minimum of 3 months experience with the N5 sound processor
* Prior documentation of sentence recognition testing in noise at a difficulty of +10 dB SNR or better
* Native English speaker
* Willingness to participate in and comply with all requirements of the protocol

Exclusion Criteria:

* Unrealistic expectations
* Unwillingness to comply with investigational requirements of the protocol
* Additional handicaps that would prevent or restrict participation in the evaluations

Primary outcomes:
measure: Endpoint 1: Evaluation of Signal to Noise Ratio - Noise Reduction
timeFrame: Visit 2, 1 month after baseline testing
measure: Endpoint 2: Evaluation of SCAN
timeFrame: Visit 2, 1 month after baseline testing
Secondary outcomes:
Other outcomes:
Locations:
city: Englewood
country: United States
facility: Rocky Mountain Ear Center
state: Colorado
city: Chesterfield
country: United States
facility: Center for Hearing and Balance
state: Missouri
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
city: Houston
country: United States
facility: Houston Ear Research Foundation
state: Texas
Study officials:
References:
Clinical trial NCT00437463: Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
Official title: Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Glomerulonephritis
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-02-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.


Eligibility criteria: Inclusion Criteria:

* biopsy-confirmed IgA nephropathy
* proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 µmol/l

Exclusion Criteria:

* pregnant or nursing mother, or women of childbearing potential without an effective method of birth control
* history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor
* evidence of clinically significant hepatic, gastrointestinal, autoimmune disease
* history of malignancy, drug or alcohol abuse
* participation in any previous trial on ACE inhibitor
* taking other investigational drugs within the past 30 days
* known history of sensitivity / allergy to ACE inhibitor

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy)
timeFrame: From the beginning to the end of the study
measure: Development of proteinuria
timeFrame: From the beginning to the end of the study
measure: 20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation
timeFrame: From the beginning to the end of the study
measure: body weight, blood pressure, pulse
timeFrame: From the beginning to the end of the study
measure: Adverse effects of treatment
timeFrame: From the beginning to the end of the study
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Sanofi-Aventis
Study officials:
affiliation: Sanofi
name: Daniel Yuen
role: STUDY_DIRECTOR
References:
Clinical trial NCT03752463: NMDA Enhancer for the Treatment of Mild Alzheimer's Disease
Official title: NMDA Enhancer for the Treatment of Mild Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alzheimer Disease
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
Collaborators: name: Ministry of Science and Technology, Taiwan
First posted: 2018-11-26
Enrollment: 154
Sex: ALL
Minimum age (years): 50
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: NMDA neurotransmission plays an important role in learning and memory. NMDA receptors (NMDAR) were found to decrease in the frontal lobe and hippocampus of Alzheimer's disease (AD). This study is a randomized, double-blind, placebo controlled drug trial for testing the efficacy of NMDAR-enhancer. All subjects will be allocated randomly to 4 groups: (1) DAOI-A group; (2) DAOI-B group; (3) DAOI-C group; (4) placebo group. The study period is 24 weeks. The investigators hypothesize that DAOI may yield better efficacy than placebo for cognitive function in patients with AD.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Alzheimer's disease
* MMSE between 10-26
* CDR 1

Exclusion Criteria:

* Hachinski Ischemic Score \> 4
* Substance abuse/dependence
* Parkinson disease, epilepsy, dementia with psychotic features
* Major depressive disorder
* Major physical illnesses
* Severe visual or hearing impairment

Primary outcomes:
measure: Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
timeFrame: week 0, 8, 16, 24
Secondary outcomes:
measure: Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input at week 8, 16 and 24
timeFrame: week 8, 16, 24
measure: Change from baseline in speed of processing (Category Fluency) at week 24
timeFrame: week 0, 24
measure: Change from baseline in working memory (Wechsler Memory Scale, Spatial Span) at week 24
timeFrame: week 0, 24
measure: Change from baseline in verbal learning and memory tests (Wechsler Memory Scale, Word Listing) at week 24
timeFrame: week 0, 24
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT02088463: Mobilization for Post Partum Low Back Pain
Official title: Efficacy of Lumbar Mobilization on Postpartum Low Back Pain in Egyptian Females: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain, Mechanical
Keywords: Mechanical LBP
Mobilization
Postpartum
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2014-03-17
Enrollment: 45
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The study was conducted to the following purposes

1. To investigate the effect of lumbar mobilization on muscle activity in postpartum mechanical low back pain.
2. To investigate the effect of lumbar mobilization on pain intensity in postpartum mechanical low back pain patients.
3. To investigate the effect lumbar mobilization on functional disability in postpartum mechanical low back pain patients.
4. To compare between the effects of lumbar mobilization, tactile stimulation (placebo treatment) and traditional treatment in postpartum mechanical low back pain patients.

Detailed description: all participants divided randomly into three groups, Group A (Study group) received PA lumbar mobilization plus traditional treatment which consisted of Ultrasonic and Infra-red. Group B (Placebo group) received placebo mobilization plus traditional treatment. Group C (Control group) received traditional treatment only

Eligibility criteria: Inclusion Criteria:

Females with LBP lasting more than 3 months since their delivery

* their age range 25-35 years old with body mass index (BMI) less than 30kg/m2

Exclusion Criteria:

* medical conditions that don't allow the subject to lie prone comfortably as, cardiovascular disease, uncontrolled hypertension, abdominal hernia, severe respiratory diseases, as well as problems in the back e.g. previous low back surgery, spinal malignancy. In addition to known rheumatic joint disease, and upper or lower motor neuron lesion that affects lower limbs

Primary outcomes:
measure: Pain intensity
timeFrame: after 4 weeks from starting the intervention
measure: functional disability
timeFrame: after 4 weeks from starting the intervention
measure: back muscle activity
timeFrame: after 4 weeks from starting the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Physical Therapy
state: Giza
Study officials:
affiliation: Assocciate Professor of Physical Therapy
name: Dalia Shewitta, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06980363: Hyaluronidase Enzymes and Local Anesthesia
Official title: Efficacy of Articaine Plus Hyaluronidase Enzymes Infiltration Versus Traditional Inferior Alveolar Nerve Block for the Extraction of Mandibular Molars
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Local Infiltration
Lead sponsor: Fayoum University
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * For both groups, local anaesthesia will be administered by one single surgeon and the extraction will be performed by another single surgeon across all subjects. The surgeon performing the extraction will be blinded with regard to the local anaesthesia technique used in this study
* A buccal infiltration injection of 1.5 ml of 4% articaine with 1:100,000 adrenaline (Septocaine, Septodont, New Castle, Del.) plus 1.5 ml of hyaluronidase enzyme (7.5IU/1ml) will be used in the study group while use 4% articaine with 1:100,000 adrenaline (Septocaine, Septodont, New Castle, Del.)only in traditional inferior alveolar nerve block in the control group
* In study and control groups, VAS (visual analogue scale=is an unmarked, continuous, horizontal,100-mm line, anchored by the end points of "no pain" on the left and "worst pain" on the right ) will be used to evaluate the pain levels of the patients associated with the injection and during extraction


Eligibility criteria: Inclusion Criteria:

* Medically stable patients
* Seeking for non surgical extraction of mandibular molar tooth

Exclusion Criteria:

* history of metabolic or systemic diseases affecting bone or healing process,

  * local infection
  * Grade III mobility
  * Neurological disorder
  * an analgesic use within 24 hours before anaesthesia administration

Primary outcomes:
measure: visual analogue scale (VAS)0_10
timeFrame: Periprocedural
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: